Neurocrine Biosciences (NBIX) Capital Expenditures (2010 - 2026)

Neurocrine Biosciences' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• Quarterly Capital Expenditures fell 86.92% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.7 million (down 34.48% YoY) and the FY2025 annual result came in at $34.0 million, down 10.99% from the prior year.
• Capital Expenditures was $1.4 million for Q1 2026 at Neurocrine Biosciences, up from -$2.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $37.4 million in Q4 2024 and bottomed at -$14.0 million in Q4 2022.
• A 5-year average of $4.5 million and a median of $600000.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 2700.0% — and 2024, when it tumbled 4050.0%.
• Neurocrine Biosciences' Capital Expenditures stood at -$14.0 million in 2022, then jumped by 111.43% to $1.6 million in 2023, then soared by 2237.5% to $37.4 million in 2024, then slumped by 106.42% to -$2.4 million in 2025, then jumped by 158.33% to $1.4 million in 2026.
• Business Quant data shows NBIX's Capital Expenditures at $1.4 million in Q1 2026, -$2.4 million in Q4 2025, and $34.5 million in Q3 2025.